CHADDS FORD, Pa., July 26, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will host a conference call and live Internet webcast on Tuesday, August 9, 2011 at 8:30 a.m. ET to discuss results for the 2011 second quarter.
David P. Holveck, president and CEO, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, Tony Bihl, group president, American Medical Systems, and Blaine Davis, vice president, corporate affairs will host the call.
Investors and other interested parties may call 866-203-2528 (domestic) or 617-213-8847 (international) and enter passcode 76257989. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from August 9, 2011 at 12:30 p.m. ET until 12:00 p.m. ET on August 23, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 82161745.
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 p.m. ET on August 23, 2011. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, Inc., HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.
|SOURCE Endo Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved